Which treatment is actually likely to apply to you

For most patients weighing up these two options, eligibility criteria do the sorting — not personal preference or clinical ranking. Whether ChondroFiller injection or MACI is the realistic path forward depends almost entirely on whether you meet a specific set of gatekeeping conditions.

MACI carries the more restrictive entry requirements. Under NICE Technology Appraisal TA477 (2017), NHS funding applies only when all four of the following conditions are met simultaneously: a focal knee cartilage defect larger than 2 cm², no prior cartilage surgery on the same knee, minimal osteoarthritis, and referral to a designated NHS tertiary centre. Missing any single criterion removes MACI from the NHS pathway.

ChondroFiller injection covers much of the patient population that falls outside those gates. It carries no minimum defect size, no upper age limit, and can be used in joints beyond the knee — including the hip, ankle, and shoulder. It is also an option for patients who have had prior cartilage procedures or who have moderate osteoarthritic change.

One boundary applies to both treatments equally: neither is appropriate where joint damage has progressed to end-stage, bone-on-bone arthritis. A mechanically stable joint with a focal lesion is the shared prerequisite.

The sections that follow examine what each treatment does and what the outcomes evidence shows — but the eligibility picture above is where most patients' decision actually begins.

How ChondroFiller injection works

At a ChondroFiller injection appointment, the clinician locates the cartilage defect under real-time ultrasound imaging and delivers the collagen solution directly into the lesion — no general anaesthetic, no operating theatre, no incision. The entire procedure takes place in an outpatient setting on Harley Street.

Once placed, the liquid scaffold self-polymerises inside the defect in approximately 3–5 minutes, forming a stable hydrogel matrix that fills and conforms to the lesion geometry. Crucially, the material is acellular — it contains no harvested cells — yet this does not prevent biological repair from beginning. The scaffold is designed to recruit the patient's own progenitor cells from the surrounding bone and synovial fluid, a process known as matrix-induced chondrogenesis. Experimental work using an ex vivo osteochondral model confirmed this mechanism, recording a 2.4-fold increase in DNA content within the scaffold by day 14, consistent with active native cell migration into the matrix.

The treatment is not confined to the knee. ChondroFiller injection can be delivered across multiple joints — including the hip, ankle, shoulder, elbow, wrist, and small hand joints — making it applicable to a broader range of cartilage injuries than many surgical alternatives. Defects up to approximately 3 cm² represent the primary indication, with treatment extendable to lesions up to 6 cm² in selected cases.

One practical consideration follows from the material's early behaviour: biomechanical testing has shown that the scaffold has limited load-bearing stability in the immediate post-injection period. Weight-bearing is therefore restricted in the days following treatment until stable defect filling is established — an important factor to discuss and plan for before the appointment.

How MACI works and how NHS access is structured

MACI sits at the more complex end of the cartilage-repair pathway, unfolding across two separate surgical episodes several weeks apart.

Stage one is a harvesting arthroscopy: the surgeon takes a small biopsy of healthy cartilage from the patient's knee under anaesthetic. That tissue is sent to a laboratory, where the chondrocytes are isolated and expanded over 4–6 weeks. Stage two is a return to theatre — arthroscopic or open surgery, again under anaesthetic — for implantation of a Type I/III collagen membrane seeded with the cultured cells. Once in place, the membrane is fixed to the prepared defect bed, and recovery from implantation carries its own restricted weight-bearing programme and extended rehabilitation.

NHS access is governed by the four NICE TA477 eligibility gates described in the opening section. Patients who clear all four are eligible for referral to a designated NHS tertiary centre; those who miss even one criterion fall outside the funded pathway entirely.

Two practical considerations are often underestimated at the planning stage. First, the weeks between procedures represent a meaningful gap in terms of time off work, logistics, and the psychological weight of waiting after an initial operation. Second, the branded MACI product is not directly distributed in the UK market, which makes private pricing less transparent than for treatments with a clear UK list price. Figures of £30,000 or above are commonly cited, but patients pursuing the private route should request an itemised quote from the treating centre directly.

Patient profiles: who tends to suit each pathway

Three variables tend to sort patients into one lane or the other: defect size, prior surgery history, and joint location.

The typical ChondroFiller injection candidate

Patients who respond well to ChondroFiller injection most often present with a focal defect of up to approximately 3 cm² — though treatment can extend to 6 cm² in selected cases — in any joint where cartilage damage has occurred. Because ChondroFiller injection carries no minimum defect-size threshold, no restriction on prior cartilage surgery, and no upper age limit, it is frequently the only active restoration option for patients who have already undergone earlier cartilage procedures or who have damage in the hip, ankle, shoulder, elbow, wrist, or small hand joints — joints for which MACI has no established NHS pathway.

One important caution for hip patients: in a cohort study with up to five years of follow-up, patients with pre-existing osteoarthritis at Tönnis grade 2–3 fared poorly. Pre-treatment imaging assessment of OA staging is therefore clinically meaningful before proceeding with ChondroFiller injection in the hip.

The typical MACI candidate

MACI is more narrowly defined. The patient profile that fits NHS NICE TA477 criteria is: a focal knee defect larger than 2 cm², no prior cartilage surgery on the same knee, near-normal surrounding joint with minimal osteoarthritis, and the capacity to complete a months-long post-operative rehabilitation programme. Private MACI at £30,000 or above is an additional consideration for those outside NHS eligibility.

What the evidence actuallyshows — and where gaps remain

ChondroFiller injection's published outcome anchors — roughly 30-point IKDC improvement, MOCART scores of 70–87/100 at one year, and symptom relief in 70–85% of patients — come from cohort-level data rather than a powered randomised trial against a surgical comparator. The reoperation rate sits at 3–8% across published series. A small RCT (n=23) compared ChondroFiller injection against microfracture and found significant IKDC gains at 3, 6, and 12 months with no adverse events; six of ten patients in the microfracture arm declined surgery after randomisation, however, leaving no meaningful comparative signal. Knee-specific outcomes beyond five years have not yet been reported — a genuine gap, though hip cohort data extending to 60 months show 17 of 21 evaluable patients achieving good or excellent results.

MACI's strongest card is durability. A 2024 systematic review covering minimum ten-year follow-up in 168 patients (188 defects, mean age 37) found sustained patient-reported outcome improvements, an all-cause reoperation rate of 9%, and progression to total knee replacement in only 7.4% of patients at ten to seventeen years — a track record that no injectable scaffold technique can currently match on a like-for-like timeframe. A 2025 three-arm RCT (n=48) tempers that picture somewhat: MACI, AMIC, and arthroscopic minced cartilage produced equivalent pain and function scores at two years, suggesting MACI's two-stage complexity does not translate into a short-term advantage over newer single-stage surgical approaches.

No head-to-head trial of ChondroFiller injection versus MACI has been published. The absence is structural as much as it is logistical: the patients who qualify for NHS MACI under NICE TA477 — focal knee defects exceeding 2 cm² with no prior cartilage surgery — and the patients who typically access ChondroFiller injection largely occupy different eligibility bands, making a directly comparable trial population difficult to assemble.

Cost, recovery, and booking an assessment

The cost difference is the most immediate practical consideration for patients who do not qualify for NHS MACI. ChondroFiller injection costs approximately £3,000–£9,800 privately, varying with defect size. MACI costs £30,000 or more privately; patients who satisfy all four NICE TA477 criteria simultaneously can access it on the NHS, but missing any single gate removes that route entirely.

Recovery diverges by a similar margin. ChondroFiller injection is a single outpatient appointment: weight-bearing is restricted in the early post-injection weeks while stable defect filling is established, then a structured return to activity follows. MACI spans two separate procedures under anaesthetic — biopsy arthroscopy first, then the implantation surgery four to six weeks later — followed by months of restricted weight-bearing rehabilitation between and after both episodes.

ChondroFiller injection at the London Cartilage Clinic

This article is published by Liquid Cartilage™, the UK platform for ChondroFiller injection. The treatment is delivered at the London Cartilage Clinic on Harley Street as an ultrasound-guided outpatient procedure. Professor Paul Y. F. Lee leads the service and can assess defect size, joint-specific imaging, and prior treatment history to establish whether ChondroFiller injection is the appropriate pathway. Appointments are available at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study comparing ChondroFiller liquid with microfracturing for focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Dataset on patient education and digital information quality in knee cartilage restoration with MACI. (2025). https://doi.org/10.1016/j.dib.2025.112353 https://doi.org/10.1016/j.dib.2025.112353
4. [4] Comparison of MACI vs AMIC vs Arthroscopic Minced Cartilage — 2-Year Follow-Up. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194
5. [5] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759